[Molecular markers as predictive factors biochemical failure after radical treatment of prostate cancer].
Clinical nomograms based on Gleason grade, tumor stage, and serum PSA are still the best predictors of prostate cancer (PC) outcome. The biotechnological  advancements achieved in the last decade represent a remarkable source for new prognostic and predictive tissue and serum molecular biomarkers. In this review,  we will summarize conventional PC prognostic biomarkers and focus on novel identified biomarkers for PC early diagnosis and progression that might be used in  the future. Although they are not ready for widespread, routine use, there are reasons to believe that future models will combine these markers with traditional  pretreatment and treatment-related variables and will improve our ability to predict outcome and select the optimal treatment.
Servicio de Oncología Radioterápica, Hospital Universitario de la Princesa, Madrid, España. azapatero.hlpr@salud.madrid.org
Almudena
A
Zapatero
Carmen
C
Martín de Vidales
Alfonso Cruz
AC
Conde
Olwen
O
Leaman
D015415:Biomarkers / Q000032:analysis; D006801:Humans; D008297:Male; D009857:Oncogenes; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000235:genetics / Q000628:therapy*
D015415:Biomarkers; D017430:Prostate-Specific Antigen